{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/guiding-biotechs-development-immunotherapy-cancer-treatment-out-box-thinking#webpage",
"url": "https://www.fortrea.com/insights/guiding-biotechs-development-immunotherapy-cancer-treatment-out-box-thinking",
"name": "Guiding a biotech’s development of an immunotherapy cancer treatment with 'out-of-the-box' thinking",
"description": "This Fortrea case study outlines how immunotherapy clinical trials for cancer treatment were supported for a biotech organization through end-to-end clinical trial services focused on early-phase development. The engagement included Phase I clinical trials, study design, protocol development, and patient recruitment in oncology trials to support the progression of a cancer immunotherapy program. The approach aligned biotech clinical development with structured operational support, enabling coordination across clinical functions and ensuring consistency in execution. By integrating immuno-oncology CRO services with centralized trial processes, the model supported efficient management of clinical activities, improved oversight, and reduced operational gaps. The case study demonstrates how end-to-end clinical trial services and focused patient recruitment in immunotherapy trials can support early-stage biotech programs in advancing cancer treatment development."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Guiding a biotech’s development of an immunotherapy cancer treatment with 'out-of-the-box' thinking",
"item": "https://www.fortrea.com/insights/guiding-biotechs-development-immunotherapy-cancer-treatment-out-box-thinking"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/guiding-biotechs-development-immunotherapy-cancer-treatment-out-box-thinking#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/guiding-biotechs-development-immunotherapy-cancer-treatment-out-box-thinking#webpage"
},
"headline": "Immunotherapy Clinical Trials for Cancer Treatment with 'out-of-the-box' thinking | Fortrea Case Study",
"description": "This Fortrea case study outlines how immunotherapy clinical trials for cancer treatment were supported for a biotech organization through end-to-end clinical trial services focused on early-phase development. The engagement included Phase I clinical trials, study design, protocol development, and patient recruitment in oncology trials to support the progression of a cancer immunotherapy program. The approach aligned biotech clinical development with structured operational support, enabling coordination across clinical functions and ensuring consistency in execution. By integrating immuno-oncology CRO services with centralized trial processes, the model supported efficient management of clinical activities, improved oversight, and reduced operational gaps. The case study demonstrates how end-to-end clinical trial services and focused patient recruitment in immunotherapy trials can support early-stage biotech programs in advancing cancer treatment development.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-11/GettyImages-1182436133.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-15",
"dateModified": "2024-10-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/guiding-biotech-development-of-an-immunotherapy-cancer-treatment.pdf",
"encodingFormat": "application/pdf"
}
}
]
}